Natco Pharma Ltd

* $NATCOPHARM has received tentative USFDA approval for Olaparib tablets, a generic oncology drug, with Alembic Pharmaceuticals set to distribute the product in the U.S. market. * The addressable U.S. market is significant, with estimated sales of ~$1.4 billion for the 12 months ended March 2026, indicating a potentially strong opportunity upon final approval and launch